Plain-English translation of NCT05024734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a personalized approach to treating intermediate-risk non-muscle invasive bladder cancer. Doctors will remove a small sample of your tumor during a routine procedure, grow it in the lab, and test it against four different medications (, , , and ) to see which one is most effective for your specific cancer. Based on those results, you'll receive the medication that performed best in your personal tumor test.
Currently, doctors choose bladder cancer medications based on general guidelines, but tumors respond differently from person to person. This trial aims to find out whether testing your individual tumor can help doctors select the most effective treatment for you, potentially improving outcomes.
First, a small sample of your tumor will be collected during a standard bladder procedure (transurethral resection). That sample will be grown in the laboratory for about 10 days and tested against four different medications to see which works best on your cancer cells. Based on those results, you'll receive weekly bladder instillations (medication placed directly into your bladder through a catheter) of the drug that worked best in your test — six treatments in total. After that, you'll be followed with standard care as your doctor normally would monitor your bladder cancer.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Switzerland